Trial Profile

Phase 2, Double-Blind, Randomized, Multicenter, Parallel, Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TNP-2092 to Treat Acute Bacterial Skin and Skin Structure Infection in Adults

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rifaquizinone (Primary) ; Vancomycin
Indications Bacterial infections; Gram-positive infections; Skin and soft tissue infections
Focus Adverse reactions
Acronyms P2_ABSSSI
Sponsors TenNor Therapeutics

13 Sep 2023 Primary endpoints has been amended as Adverse Events endpoint has been removed and trial focus has now shifted to only Tu.
13 Jan 2022 Primary endpoints has been amended as Early Clinical Response endpoint has been added and trial focus has now shifted to Tu and Ar.
25 Feb 2020 Planned End Date changed from 1 Jan 2020 to 1 Jun 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com